Novartis Stock Falls 12% on Its Third Trial Setback In a Week — Live Feedhttps://www.live-feeds.com/feed/novartis-stock-falls-12-on-its-third-trial-setback-in-a-weekContinuously updated, source-cited coverage. Novartis Plummets Following Third Drug Trial Setbackhttps://www.live-feeds.com/feed/novartis-stock-falls-12-on-its-third-trial-setback-in-a-weekhttps://www.live-feeds.com/feed/novartis-stock-falls-12-on-its-third-trial-setback-in-a-week#u63729Thu, 10 Sep 2026 08:21:01 +0000Novartis shares tumbled between 10% and 12% following three consecutive clinical trial setbacks within a single week. The sharp decline marks one of the worst trading days for the pharmaceutical major in over twenty years. The losses accelerated after a critical Phase 3 study for a neuromuscular and dystrophy drug failed to meet expectations. This RNA treatment served as the centerpiece of a $12 billion Avidity buyout. Sympathy drops also hit other sector stocks including DYN and SRPT as investors reassessed the stability of the drug pipeline.Why it mattersThe string of consecutive pipeline fa